Children’s Hospital of Philadelphia (CHOP) has licensed a glypican 2 (GPC2) chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of neuroblastoma, a rare cancer impacting the developing nervous system, to Tmunity Therapeutics, Inc., a privately-held biopharmaceutical company.
CHOP investigators John Maris, MD, and Kristopher Bosse, MD, identified and validated the oncoprotein GPC2. It is a highly expressed on neuroblastomas but not detectable at appreciable levels in normal childhood tissues. The scientists published their findings in Cancer Cell in 2017.
They determined that GPC2 may be less susceptible to immune escape mechanisms due to its requirement for neuroblastoma proliferation. The work validated GPC2 as a nonmutated neuroblastoma oncoprotein and established a strong foundation for GPC2 as an immunotherapeutic target.
Dr. Bosse reports, “This new collaboration builds upon our prior studies and pairs Tmunity’s experience in engineering and developing CAR-T cells with CHOP’s expertise in the biology of this family of cell surface molecules across neuroblastoma and several other cancers.”
Tmunity Therapeutics Inc.
Tmunity, a privately-held, clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy. Founded in 2015, the company has raised $155 million in venture capital funding.
The company integrates broad collaborations with the University of Pennsylvania (UPenn) and the University of Minnesota with the groundbreaking scientific, clinical, and manufacturing expertise and demonstrated track record of its founders. They are developing personalized immunotherapies for cancer, infectious disease, and autoimmune disease that are advancing rapidly toward the clinic. They are headquartered in Philadelphia and utilize laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA.
Dr. Kristopher Bosse, MD assistance professor of pediatrics, Perelman School of Medicine, University of Pennsylvania, and CHOP
Dr. John Maris, MD, pediatric oncologist at Children’s Hospital of Philadelphia, co-head of the Pediatric Cancer Team and holds the Giulio D’Angelo Chair in Neuroblastoma Research
Call to Action: Interested in tracking GPC2? Sign up for our newsletter and TrialSite News will send you updates.Source: Manchester Times